Literature DB >> 22398287

Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes.

Rong Hai1, Florian Krammer, Gene S Tan, Natalie Pica, Dirk Eggink, Jad Maamary, Irina Margine, Randy A Albrecht, Peter Palese.   

Abstract

The influenza virus hemagglutinin molecule possesses a globular head domain that mediates receptor binding and a stalk domain at the membrane-proximal region. We generated functional influenza viruses expressing chimeric hemagglutinins encompassing a variety of globular head and stalk combinations, not only from different hemagglutinin subtypes but also from different hemagglutinin phylogenetic groups. These chimeric recombinant viruses possess growth properties similar to those of wild-type influenza viruses and can be used as reagents to measure domain-specific antibodies in virological and immunological assays.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22398287      PMCID: PMC3347257          DOI: 10.1128/JVI.00137-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs.

Authors:  Zhongying Chen; Weijia Wang; Helen Zhou; Amorsolo L Suguitan; Cindy Shambaugh; Lomi Kim; Jackie Zhao; George Kemble; Hong Jin
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

2.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

Authors:  T Muster; R Guinea; A Trkola; M Purtscher; A Klima; F Steindl; P Palese; H Katinger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

3.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

4.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

5.  Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza.

Authors:  John Steel; Anice C Lowen; Lindomar Pena; Matthew Angel; Alicia Solórzano; Randy Albrecht; Daniel R Perez; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

6.  Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.

Authors:  Taia T Wang; Gene S Tan; Rong Hai; Natalie Pica; Erin Petersen; Thomas M Moran; Peter Palese
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

7.  Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus.

Authors:  Rafael A Medina; Balaji Manicassamy; Silke Stertz; Christopher W Seibert; Rong Hai; Robert B Belshe; Sharon E Frey; Christopher F Basler; Peter Palese; Adolfo García-Sastre
Journal:  Nat Commun       Date:  2010-06-15       Impact factor: 14.919

8.  Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

Authors:  Rong Hai; Luis Martínez-Sobrido; Kathryn A Fraser; Juan Ayllon; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

9.  Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol.

Authors:  Nicole M Bouvier; Anice C Lowen; Peter Palese
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

10.  Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity.

Authors:  G N Rogers; J C Paulson; R S Daniels; J J Skehel; I A Wilson; D C Wiley
Journal:  Nature       Date:  1983 Jul 7-13       Impact factor: 49.962

View more
  148 in total

1.  Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins.

Authors:  Chi-Jene Chen; Megan E Ermler; Gene S Tan; Florian Krammer; Peter Palese; Rong Hai
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

2.  Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin.

Authors:  Peter H Goff; Florian Krammer; Rong Hai; Christopher W Seibert; Irina Margine; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

3.  Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.

Authors:  Florian Krammer; Rong Hai; Mark Yondola; Gene S Tan; Victor H Leyva-Grado; Alex B Ryder; Matthew S Miller; John K Rose; Peter Palese; Adolfo García-Sastre; Randy A Albrecht
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

4.  Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA).

Authors:  Steven F Baker; Aitor Nogales; Felix W Santiago; David J Topham; Luis Martínez-Sobrido
Journal:  Vaccine       Date:  2015-06-01       Impact factor: 3.641

Review 5.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

Review 6.  Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.

Authors:  James E Crowe
Journal:  Cell Host Microbe       Date:  2017-08-09       Impact factor: 21.023

7.  Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.

Authors:  Peter H Goff; Tomoko Hayashi; Luis Martínez-Gil; Maripat Corr; Brian Crain; Shiyin Yao; Howard B Cottam; Michael Chan; Irene Ramos; Dirk Eggink; Mitra Heshmati; Florian Krammer; Karen Messer; Minya Pu; Ana Fernandez-Sesma; Peter Palese; Dennis A Carson
Journal:  J Virol       Date:  2015-01-07       Impact factor: 5.103

Review 8.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

9.  Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies.

Authors:  Florian Krammer; Natalie Pica; Rong Hai; Irina Margine; Peter Palese
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

10.  A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies.

Authors:  Mark J Bailey; Felix Broecker; Paul E Leon; Gene S Tan
Journal:  J Vis Exp       Date:  2018-02-23       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.